The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2022 | RED LaIT-SABR: predictive factors for polymetastatic progression of CRC lung oligometastases
Luca Nicosia, MD, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, discusses the RED LaIT-SABR study, which aimed to identify predictive factors for polymetastatic progression in patients with colorectal cancer lung oligometastases. Polymetastatic progression was defined as a patient having more than five new metastatic lesions. The number of metastases and lesion diameter were identified as factors of polymetastatic progression. The study found that the number of metastases was not enough to define oligometastatic status because a patient identified as having oligometastatic disease from a numerical stance could rapidly progress to polymetastatic disease when the cumulative tumor volume was high. Due to the complex nature of the disease, clinicians should adopt a personalized approach which considers more than the sole number of metastases. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
